Loxo Oncology, Inc. Form 3/A August 07, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

Expires:

response...

3235-0104

January 31, 2005

0.5

Estimated average burden hours per

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

3200 WALNUT ST

1. Name and Address of Reporting Person *

ARRAY BIOPHARMA INC

(Last) (First)

(Street)

(Middle)

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Statement

(Month/Day/Year)

07/31/2014

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

_X__ 10% Owner Director Officer Other (give title below) (specify below)

Loxo Oncology, Inc. [LOXO]

5. If Amendment, Date Original Filed(Month/Day/Year)

08/01/2014

6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting

Form filed by More than One

Reporting Person

BOULDER, Â COÂ 80301

(City) (State)

1. Title of Security (Instr. 4)

(Zip)

2. Amount of Securities Beneficially Owned

(Instr. 4)

Ownership Form:

Direct (D) or Indirect (I) (Instr. 5)

SEC 1473 (7-02)

Table I - Non-Derivative Securities Beneficially Owned

4. Nature of Indirect Beneficial

Ownership (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

> Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying **Derivative Security** (Instr. 4)

4. Conversion or Exercise

Price of

Security

Derivative

5. Derivative

6. Nature of Indirect Ownership Beneficial Ownership Form of (Instr. 5)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Security: Direct (D) or Indirect (I) (Instr. 5)

Series A-1 Convertible Preferred Stock

(1)

 $\begin{array}{cc} \hat{A} & \underline{^{(1)}} & & Common \\ & Stock & \end{array}$

1,609,560 \$ 0 (1)

D Â

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

ARRAY BIOPHARMA INC 3200 WALNUT ST BOULDER, COÂ 80301

Â X Â Â

Signatures

John R. Moore, Vice President and General Counsel

08/07/2014

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This amendment is being filed because the number of shares reported in the reporting person's original Form 3 did not reflect shares issued pursuant to a 1.6525 to 1 forward stock split on July 21, 2014. As of the date of the original Form 3, the reporting person holds an

(1) aggregate of 500,704 shares of Series A-I Convertible Preferred Stock which are convertible into 1,609,560 shares of common stock of the issuer upon the consummation of the issuer's initial public offering pursuant to an effective registration statement on Form S-1. The convertible securities convert automatically upon such event and have no expiration date or conversion price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2